Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

CEO

Mr. Sanjeev Luther

Employees

Country

United States

ISIN

US1140821182

Listings

0 Comments

Share your thoughts

FAQ

What is Ernexa Therapeutics stock price today?▼

The current price of ERNAW is $0.03 USD — it has decreased by -39.68% in the past 24 hours. Watch Ernexa Therapeutics stock price performance more closely on the chart.

What is Ernexa Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Ernexa Therapeutics stocks are traded under the ticker ERNAW.

When is the next Ernexa Therapeutics earnings date?▼

Ernexa Therapeutics is going to release the next earnings report on May 20, 2026.

How many employees does Ernexa Therapeutics have?▼

As of April 13, 2026, the company has 6 employees.

In which sector is Ernexa Therapeutics located?▼

Ernexa Therapeutics operates in the Other sector.

When did Ernexa Therapeutics complete a stock split?▼

Ernexa Therapeutics has not had any recent stock splits.

Where is Ernexa Therapeutics headquartered?▼

Ernexa Therapeutics is headquartered in Cambridge, United States.